Standard BioTools (NASDAQ:LAB) Releases Earnings Results, Misses Expectations By $0.06 EPS

Posted by Brian Himes on Aug 5th, 2026

Standard BioTools (NASDAQ:LAB – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.06), FiscalAI reports. The firm had revenue of $20.10 million during the quarter, compared to the consensus estimate of $20.80 million. Standard BioTools had a negative return on equity of 8.18% and a net margin of 73.46%.

Standard BioTools Stock Down 4.4%

Shares of NASDAQ LAB traded down $0.04 during midday trading on Wednesday, reaching $0.78. 2,153,794 shares of the company’s stock traded hands, compared to its average volume of 2,756,311. The company has a market cap of $306.09 million, a price-to-earnings ratio of 3.92 and a beta of 1.40. The stock’s 50 day simple moving average is $0.89 and its 200-day simple moving average is $1.02. Standard BioTools has a one year low of $0.70 and a one year high of $1.72.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in LAB. Deutsche Bank AG lifted its stake in shares of Standard BioTools by 4.4% during the 4th quarter. Deutsche Bank AG now owns 255,851 shares of the company’s stock worth $327,000 after purchasing an additional 10,824 shares during the last quarter. California State Teachers Retirement System lifted its position in shares of Standard BioTools by 20.9% during the fourth quarter. California State Teachers Retirement System now owns 254,465 shares of the company’s stock valued at $326,000 after buying an additional 43,925 shares during the last quarter. XTX Topco Ltd grew its position in shares of Standard BioTools by 1,492.3% in the 4th quarter. XTX Topco Ltd now owns 206,903 shares of the company’s stock worth $265,000 after buying an additional 193,909 shares during the last quarter. Front Street Capital Management Inc. bought a new position in shares of Standard BioTools during the 2nd quarter worth approximately $145,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in Standard BioTools by 47.8% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 108,416 shares of the company’s stock valued at $139,000 after acquiring an additional 35,069 shares during the last quarter. 53.74% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Standard BioTools from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, July 21st. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $1.35.

View Our Latest Stock Analysis on LAB

Standard BioTools Company Profile

(Get Free Report)

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.